|Cancer Stem Cell News 5.39 October 5, 2016|
Investigators identified that lysine demethylase KDM3A as a critical regulator of ovarian cancer stemness and cisplatin resistance by inducing the expressions of pluripotent molecules Sox2 and Nanog and anti-apoptotic B-cell lymphoma 2, respectively. [Oncogene]
Researchers present evidence that specific histone deacetylases (HDACs) play essential roles in the cancer stem cell (CSC) phenotype. Utilizing a novel CSC model, they discovered that the HDACs, HDAC1 and HDAC7, are specifically over-expressed in CSCs when compared to non-stem-tumor-cells. [Oncogene]
The authors report the isolation and propagation of neuroblastoma sphere-forming cells with self-renewal and differentiation potential from tumors of the TH-MYCN mouse, an animal model of high-risk neuroblastoma with MYCN amplification. [Cell Reports]
Scientists elucidate underlying mechanism of the regulation, and find that miR-612 inversely modulated the mRNA and protein level of epithelial cell adhesion molecule as well as CD133, negatively regulated the numbers and sizes of tumor spheres, directly inhibited the protein level of Sp1, and subsequently reduce transcription activity of Nanog. [Cell Death Dis]
The authors showed that a comparable population of small stem cells can be found in the ovarian tissue of women with borderline ovarian cancer, which, in contrast to small stem cells in “healthy” ovaries, formed spontaneous tumor-like structures and expressed some markers related to pluripotency and germinal lineage. [Sci Rep]
Scientists used xenograft tumor murine models to suggest that antiangiogenic agents actually increase the invasive and metastatic properties of lung cancer cells. In their experiments with murine lung cancer xenografts, they found that the antiangiogenic agent endostatin increased the population of ALDH+ cells, and did so by generating intratumoral hypoxia in the xenografts. [Sci Rep]
To elucidate the role of Gal3 in breast cancer stem cells, investigators performed various in vitro and in vivo studies such as sphere-formation assays, Western blotting, flow cytometric apoptosis assays, and limited dilution xenotransplant models. Histological staining for Gal3 in tissue microarrays of breast cancer patients was performed to analyze the relationship of clinical outcome and Gal3 expression. [Breast Cancer Res]
Scientists found that overexpression of HSP47 promotes primary glioma cell tumor formation, invasion, angiogenesis and stem-like properties. The overexpression of HSP47 was correlated and promoted extracellular matrix related genes through TGF-β pathway in glioblastoma multiforme. [ACS Chem Neurosci]
The authors demonstrated activin pathway enhanced the colorectal cancer stem cells self-renew and contribute to colorectal cancer progression in vivo. Targeting activin pathway potentially provides an effective strategy for colorectal cancer therapy. [Biochem Biophys Res Commun]
A better understanding of cancer stem cells (CSCs) biology, as well as more accurate study design, may maximize the therapeutic effects of these agents. In this respect, it is important to establish: i) which molecules should be targeted; ii) what drug combinations may be suitable; iii) which patient settings will CSC targeting offer the highest clinical benefit; and iv) how to integrate therapeutic approaches targeting CSCs with standard cancer therapy. [Expert Opin Drug Discov]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
PharmaMar will present new clinical data from its antitumoral compounds of marine origin: Yondelis® (trabectedin) and lurbinectedin (PM1183). Results to be presented in both oral presentations and posters include single-agent lurbinectedin Phase II trial in patients with BRCA 1/2-associated metastatic breast cancer and Phase III prospective study carried out in France, which compares trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma. [Press release from PharmaMar discussing research to be presented at the 2016 European Society of Medical Oncology (ESMO), Copenhagen]
Biocept, Inc. announced that clinical results featuring its liquid biopsy platform will be presented. Study results highlighting the concordance and clinical utility of detecting actionable biomarkers in patients with advanced non-small cell lung cancer will be presented by Lourdes Barrera, Ph.D., Diagnostics Manager, AstraZeneca Oncology BU, Mexico. [Press release from Biocept, Inc. discussing research to be presented at the 2016 European Society of Medical Oncology (ESMO), Copenhagen]
Tocagen Inc. announced updated clinical data for Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (extended-release 5-fluorocytosine) for the treatment of recurrent high grade glioma. [Press release from Tocagen Inc. discussing research presented at the 10th International Oncolytic Virus Meeting, Vancouver]
Dr. Allen Eaves, Chairman, President and Chief Executive Officer of STEMCELL Technologies, a global biotechnology company that supplies tools and services to enable life science research, is this year’s Entrepreneur Of The Year Pacific winner. [Ernst & Young (CNW Group Ltd.)]
The National Institutes of Health, as part of its national Precision Medicine Initiative Cohort Program, has expanded a five-year funding award to The Scripps Research Institute (TSRI) from $120 million to $207 million. [The Scripps Research Institute]
Personal Genome Diagnostics Inc. announced the launch of its PlasmaSELECTTM 64 targeted panel for pan-cancer tumor profiling. PlasmaSELECT 64 identifies clinically actionable and functionally important sequence mutations and structural alterations across multiple cancer types without the need for invasive biopsies. [Personal Genome Diagnostics Inc.]
Halozyme Therapeutics, Inc. announced that its investigational drug, PEGPH20, and a companion diagnostic assay for assessment of hyaluronan under development by Ventana Medical Systems, Inc. will be included in a groundbreaking pancreatic cancer clinical trial initiative called Precision Promise. [Halozyme Therapeutics, Inc.]
The 9-month-old patent battle over CRISPR, a novel genome-editing tool that could have immense commercial value, has taken two surprising twists. Last week, attorneys for the Broad Institute in Cambridge, Massachusetts, one of the research organizations vying for CRISPR rights, submitted motions that could let it win even if it loses. [Science Insider]
Scientists are turning to a software–development site to share data and code. [Nature Toolbox]
From designer babies to engineered mosquitoes, advances in genome-editing technologies such as CRISPR–Cas9 have raised the possibility of tremendous scientific advances — and serious ethical concerns. [Nature News]
Biomedical experts plan to create a scoring system that will help researchers choose reliable antibodies for their experiments. The only problems: figuring out how such a ranking would work — and getting manufacturers to adopt the standard. [Nature News]
NEW Cancer Metabolism and the Tumor Microenvironment Conference
NEW Advances in Cell Engineering, Imaging and Screening
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.
Home Cancer Stem Cell News Volume 5.39 | Oct 5 2016